May 11, 2021
Results of a Phase 2 clinical trial from Vapogenix’s lead wound pain program were presented by Prof. Michael Woodward, AM, Director of Wound Clinic, Austin Health, Australia in a presentation entitled “Analgesic efficacy, safety and tolerability of VPX638 (sevoflurane) administered topically to patients with painful wounds” at the Wounds Australia 2020 Virtual Conference on May 5, 2021.
This randomized, double-blind, placebo-controlled, multi-centre study was conducted in 78 subjects, to evaluate the analgesic efficacy, safety and tolerability of a non-opioid, novel class of topical analgesic, VPX638 (sevoflurane) in painful wounds. VPX638 or matching saline placebo was administered topically into the wound following dressing removal, and again immediately after wound cleaning. Pain scores (0-10 scale) and use of analgesia was recorded for 24 hrs. Although pre-specified endpoints were not met in this early study, post-hoc analyses revealed clinically meaningful analgesia. VPX638 treatment resulted in rapid, large and clinically meaningful analgesic effect (3.8, 95% CI:2.4-5.2 pain decrease) within 15 mins. The analgesia was sustained and analyses of the Summed Pain Intensity Difference over 8, 12 and 24 hrs showed a statistically significant difference from placebo (p=0.016, 0.009, 0.0495, respectively). The median duration of analgesia was 24.3 hrs for VPX638 and 7.1 hrs for placebo, p=0.0065. VPX638 treatment also resulted in a 50% decrease in opioid use compared with placebo during 24 hrs after drug administration. VPX638 was well tolerated with no local wound effects, no evidence of systemic effects, and no other safety signals.
The study showed that VPX638 has the potential to become the standard of care for the treatment of wound pain, due to its rapid onset of action, sustained analgesia, and opioid-sparing properties.
Results of a Phase 2 clinical trial from Vapogenix’s lead wound pain program were presented by Prof. Michael Woodward, AM, Director of Wound Clinic, Austin Health, Australia in a presentation entitled “Analgesic efficacy, safety and tolerability of VPX638 (sevoflurane) administered topically to patients with painful wounds” at the Wounds Australia 2020 Virtual Conference on May 5, 2021.
This randomized, double-blind, placebo-controlled, multi-centre study was conducted in 78 subjects, to evaluate the analgesic efficacy, safety and tolerability of a non-opioid, novel class of topical analgesic, VPX638 (sevoflurane) in painful wounds. VPX638 or matching saline placebo was administered topically into the wound following dressing removal, and again immediately after wound cleaning. Pain scores (0-10 scale) and use of analgesia was recorded for 24 hrs. Although pre-specified endpoints were not met in this early study, post-hoc analyses revealed clinically meaningful analgesia. VPX638 treatment resulted in rapid, large and clinically meaningful analgesic effect (3.8, 95% CI:2.4-5.2 pain decrease) within 15 mins. The analgesia was sustained and analyses of the Summed Pain Intensity Difference over 8, 12 and 24 hrs showed a statistically significant difference from placebo (p=0.016, 0.009, 0.0495, respectively). The median duration of analgesia was 24.3 hrs for VPX638 and 7.1 hrs for placebo, p=0.0065. VPX638 treatment also resulted in a 50% decrease in opioid use compared with placebo during 24 hrs after drug administration. VPX638 was well tolerated with no local wound effects, no evidence of systemic effects, and no other safety signals.
The study showed that VPX638 has the potential to become the standard of care for the treatment of wound pain, due to its rapid onset of action, sustained analgesia, and opioid-sparing properties.
May 10, 2021
Dr. Heather Giles, Chief Scientific Officer of Vapogenix, will present a talk entitled "An overview of volatile anesthetics and their applications in pain therapeutics" at the Pain Therapeutics 2021 Virtual Conference on Tuesday, May 11, 2021.
Dr. Heather Giles, Chief Scientific Officer of Vapogenix, will present a talk entitled "An overview of volatile anesthetics and their applications in pain therapeutics" at the Pain Therapeutics 2021 Virtual Conference on Tuesday, May 11, 2021.
November 11, 2020
Vapogenix Awarded A $1.5M Phase II SBIR Grant to Develop Groundbreaking Topical Therapy for Painful Inflammatory Conditions Affecting Millions
The grant supports Vapogenix’s development of a novel topical medicine, based on the unique analgesic and anti-inflammatory properties of volatile anesthetics (VAs) to treat inflammatory pain associated with musculoskeletal diseases such as rheumatoid arthritis, gout and osteoarthritis, which affect millions of Americans.
Vapogenix Awarded A $1.5M Phase II SBIR Grant to Develop Groundbreaking Topical Therapy for Painful Inflammatory Conditions Affecting Millions
The grant supports Vapogenix’s development of a novel topical medicine, based on the unique analgesic and anti-inflammatory properties of volatile anesthetics (VAs) to treat inflammatory pain associated with musculoskeletal diseases such as rheumatoid arthritis, gout and osteoarthritis, which affect millions of Americans.
January 7, 2020
Vapogenix Meeting with Partners, Investors at JP Morgan Healthcare Conference
Vapogenix announced today its management team will hold partnering and investor meetings January 13 to January 16, 2020, in San Francisco concurrent with the annual JP Morgan Healthcare Conference.
Vapogenix Meeting with Partners, Investors at JP Morgan Healthcare Conference
Vapogenix announced today its management team will hold partnering and investor meetings January 13 to January 16, 2020, in San Francisco concurrent with the annual JP Morgan Healthcare Conference.
November 7, 2019
Vapogenix to Attend BIO-Europe® 2019
Vapogenix will be present at the Bio-Europe 2019 meeting in Hamburg, Germany from November 11th to 13th
We are seeking partners and funding to advance our portfolio programs.
For further information please contact:
Vapogenix to Attend BIO-Europe® 2019
Vapogenix will be present at the Bio-Europe 2019 meeting in Hamburg, Germany from November 11th to 13th
We are seeking partners and funding to advance our portfolio programs.
For further information please contact:
|
Vapogenix, Inc.
Heather Giles PhD CEO and Chief Scientific Officer Mobile +1 713 4804963 Email: [email protected] |
Lighthouse BioPartners
David J. Tomasso Partner Office: +1 (919) 533-9107 Mobile: +1 (919) 368-0184 Email: [email protected] |
Steve Levine
Partner Main: +1 (888) 958-2077, x101 Direct: +1 (919) 533-9112 Mobile: +1 (919) 270-7323 Email: [email protected] |
October 29, 2019
Vapogenix Reports Encouraging Phase II Results of Topical Non-Opioid Pain Medication
Vapogenix, Inc., a clinical-stage company developing a new class of topical non-opioid, lidocaine-free analgesics, today announced results of a Phase II clinical trial of its lead product, VPX638, which demonstrates rapid onset and sustained duration of pain relief and reduced opioid use for patients with painful wounds.
Vapogenix Reports Encouraging Phase II Results of Topical Non-Opioid Pain Medication
Vapogenix, Inc., a clinical-stage company developing a new class of topical non-opioid, lidocaine-free analgesics, today announced results of a Phase II clinical trial of its lead product, VPX638, which demonstrates rapid onset and sustained duration of pain relief and reduced opioid use for patients with painful wounds.
March 9, 2018
Dr. Heather Giles, the Chief Scientific Officer of Vapogenix, speaks to ABC radio, about our ongoing clinical trial in Australia on a novel topical analgesic treatment for painful wounds.
The interview begins at the 12:31 mark:
Dr. Heather Giles, the Chief Scientific Officer of Vapogenix, speaks to ABC radio, about our ongoing clinical trial in Australia on a novel topical analgesic treatment for painful wounds.
The interview begins at the 12:31 mark:
March 9, 2018
Mackay hospital trial offers hope for sufferers of pain from non-healing wounds
A new drug being trialled in a regional Queensland hospital could provide much needed pain relief to patients suffering from non-healing wounds.
Doctor Heather Giles, the chief scientist of the Houston-based firm, said “the as-yet-unnamed topical medication could provide a long-awaited breakthrough for those afflicted by non-healing wounds. Of all the other unpleasant things that come with a wound, pain is the number one problem."
Mackay hospital trial offers hope for sufferers of pain from non-healing wounds
A new drug being trialled in a regional Queensland hospital could provide much needed pain relief to patients suffering from non-healing wounds.
Doctor Heather Giles, the chief scientist of the Houston-based firm, said “the as-yet-unnamed topical medication could provide a long-awaited breakthrough for those afflicted by non-healing wounds. Of all the other unpleasant things that come with a wound, pain is the number one problem."
May 26, 2017
Vapogenix in the WSJ Pro Venture Capital
“A decade ago concern about opioids and other systemic pain-relievers was much lower, said Danguole Altman, CEO of Vapogenix Inc., a Houston-based developer of topical medicines for wounds and other painful conditions. Amid the opioid epidemic, attitudes have changed.”
“Unlike five or 10 years ago,” Ms. Altman said, “there’s much [more] understanding that having locally acting solutions really makes a lot of sense.”
Vapogenix in the WSJ Pro Venture Capital
“A decade ago concern about opioids and other systemic pain-relievers was much lower, said Danguole Altman, CEO of Vapogenix Inc., a Houston-based developer of topical medicines for wounds and other painful conditions. Amid the opioid epidemic, attitudes have changed.”
“Unlike five or 10 years ago,” Ms. Altman said, “there’s much [more] understanding that having locally acting solutions really makes a lot of sense.”
December 2016
Five Alumni Named 2016-17 Donaldson Fellows
The Yale School of Management has named five alumni as Donaldson Fellows for 2016-2017, recognizing them as embodying the school’s mission to educate leaders for business and society in their personal and professional accomplishments.
Five Alumni Named 2016-17 Donaldson Fellows
The Yale School of Management has named five alumni as Donaldson Fellows for 2016-2017, recognizing them as embodying the school’s mission to educate leaders for business and society in their personal and professional accomplishments.
December 13 - 15, 2016
Vapogenix at the British Pharmacological Society's annual meeting
Pharmacology 2016 - London, UK
Dr. Sergio Parra and Dr. Heather Giles attended the meeting and presented the poster:
Vapogenix at the British Pharmacological Society's annual meeting
Pharmacology 2016 - London, UK
Dr. Sergio Parra and Dr. Heather Giles attended the meeting and presented the poster:
- Development of a novel human pain model: A robust pinprick methodology to evaluate cutaneous pain, and efficacy of analgesics, C Bascoul, S Parra, J D Bean-Lijewski, and H Giles
December 8, 2016
Vapogenix Secures $8.2 Million in Series C Funding
Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the company announced today. Pamoja Capital, prominent pain physicians and others invested in the round. The financial support will fund a Phase 2 Proof-of-Concept study for Project AWARD (A Wound Analgesic with RapiD action).
Vapogenix Secures $8.2 Million in Series C Funding
Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the company announced today. Pamoja Capital, prominent pain physicians and others invested in the round. The financial support will fund a Phase 2 Proof-of-Concept study for Project AWARD (A Wound Analgesic with RapiD action).
May 10 - 14, 2016
Vapogenix at APS
American Pain Society - 35th Annual Scientific Meeting - Austin, TX
Dr. Cécile Bascoul-Colombo, Dr. Sergio Parra and Dr. Heather Giles attended the 35th American Pain Society’s Annual Meeting. Vapogenix presented two posters at this meeting:
Vapogenix at APS
American Pain Society - 35th Annual Scientific Meeting - Austin, TX
Dr. Cécile Bascoul-Colombo, Dr. Sergio Parra and Dr. Heather Giles attended the 35th American Pain Society’s Annual Meeting. Vapogenix presented two posters at this meeting:
- Development of a novel human pain model: a robust and reproducible pinprick methodology to evaluate cutaneous pain sensitivity, C Bascoul-Colombo, S Parra, J D Bean-Lijewski, and H Giles
- Chronic leg ulcer pain – a need for effective topical analgesia, S Parra, P Lacouture, and H Giles
May 3, 2016
Vapogenix recognized as a most innovative company received a Top 5 Venture Award
Vapogenix, Inc was recognized as one of the most innovative companies in Texas and was awarded a Top 5 Venture Award at the Healthcare Texas Innovation Capital Conference on May 3rd, 2016 in Austin, TX.
Vapogenix recognized as a most innovative company received a Top 5 Venture Award
Vapogenix, Inc was recognized as one of the most innovative companies in Texas and was awarded a Top 5 Venture Award at the Healthcare Texas Innovation Capital Conference on May 3rd, 2016 in Austin, TX.
May 21, 2015
Vapogenix Garners Most Promising Life Science Company Award at the 2015 Texas Life Science Forum
HOUSTON, Texas - Vapogenix, Inc. took home the Most Promising Life Science Company Award at the 2015 Texas Life Science Forum which was held on May 20th at Rice University's BioScience Research Collaborative building located just off the Rice campus near the Texas Medical Center.
The forum, hosted by BioHouston, Inc., Rice Alliance and Texas Healthcare and Bioscience Institute, is the annual science gathering in Texas showcasing over 50 emerging companies, technologies, and scientific developments to an audience of over 500 investors, industry executives, entrepreneurs, and researchers from across the state. Judges were non-Houston based investors.
Vapogenix Garners Most Promising Life Science Company Award at the 2015 Texas Life Science Forum
HOUSTON, Texas - Vapogenix, Inc. took home the Most Promising Life Science Company Award at the 2015 Texas Life Science Forum which was held on May 20th at Rice University's BioScience Research Collaborative building located just off the Rice campus near the Texas Medical Center.
The forum, hosted by BioHouston, Inc., Rice Alliance and Texas Healthcare and Bioscience Institute, is the annual science gathering in Texas showcasing over 50 emerging companies, technologies, and scientific developments to an audience of over 500 investors, industry executives, entrepreneurs, and researchers from across the state. Judges were non-Houston based investors.
March 4, 2015
Vapogenix Concludes $5.1M in Series B Financing
HOUSTON - Vapogenix, Inc., a clinical stage pharmaceutical company that is developing a new class of non-narcotic, locally-acting analgesics, announced today the completion of a $5.1M Series B Preferred Stock financing of the Company, led by Pamoja Capital and GPG Ventures.
Vapogenix Concludes $5.1M in Series B Financing
HOUSTON - Vapogenix, Inc., a clinical stage pharmaceutical company that is developing a new class of non-narcotic, locally-acting analgesics, announced today the completion of a $5.1M Series B Preferred Stock financing of the Company, led by Pamoja Capital and GPG Ventures.
April 30 - May 3, 2014
Vapogenix at APS
American Pain Society - 33rd Annual Scientific Meeting - Tampa, FL
Vapogenix at APS
American Pain Society - 33rd Annual Scientific Meeting - Tampa, FL
July 3, 2013
Houston Startup Vapogenix Aims to Build a Better Pain Drug
Houston Startup Vapogenix Aims to Build a Better Pain Drug Treating pain usually means taking medication that has to course through our bloodstream—our entire body—before it can take effect.
The thing is, we typically feel pain in one place. So why can’t we just treat that specific area, and in a faster fashion? Houston-based Vapogenix is working on a drug that could do exactly that.
“Our core drug goes through skin in five minutes,” says Danguole Altman, Vapogenix’s president and CEO.
Houston Startup Vapogenix Aims to Build a Better Pain Drug
Houston Startup Vapogenix Aims to Build a Better Pain Drug Treating pain usually means taking medication that has to course through our bloodstream—our entire body—before it can take effect.
The thing is, we typically feel pain in one place. So why can’t we just treat that specific area, and in a faster fashion? Houston-based Vapogenix is working on a drug that could do exactly that.
“Our core drug goes through skin in five minutes,” says Danguole Altman, Vapogenix’s president and CEO.
October 9, 2012
Vapogenix Named Top 10 Presenting Company for MEDVENTURES 2012
Vapogenix, Inc. produced a quick-acting local anesthetic, thereby reducing systemic side effects caused by other existing analgesics. (HOUSTON, TX)
Vapogenix Named Top 10 Presenting Company for MEDVENTURES 2012
Vapogenix, Inc. produced a quick-acting local anesthetic, thereby reducing systemic side effects caused by other existing analgesics. (HOUSTON, TX)
August 3, 2012
Two Houston companies receive Texas Emerging Technology Fund awards
Rebellion Photonics and Vapogenix Inc. have been selected to receive awards from the Texas Emerging Technology Fund, Gov. Rick Perry said Friday.
Two Houston companies receive Texas Emerging Technology Fund awards
Rebellion Photonics and Vapogenix Inc. have been selected to receive awards from the Texas Emerging Technology Fund, Gov. Rick Perry said Friday.
June 17, 2010 and March 8, 2012
Vapogenix was awarded a Most Promising Life Science Company in Texas
Award at the Texas Life Science Venture Forum.
Vapogenix was awarded a Most Promising Life Science Company in Texas
Award at the Texas Life Science Venture Forum.